AbCellera
AbCellera is seeking a scientific leader in computational biology to advance structure-guided protein engineering for monoclonal antibody therapeutics. The role involves collaboration with wet-lab teams to improve antibody affinity, specificity, and developability, using in-silico models enhanced with real-world data.
Headquarters
Vancouver, British Columbia, Canada
Company Size
501-1000 employees
Founded
2012
AbCellera is a biotechnology company that discovers and develops therapeutic antibodies using a proprietary high-throughput single‑cell screening platform combined with machine learning and large immune datasets. It partners with pharma and biotech to rapidly identify and optimize antibody leads and also advances its own pipeline of first‑in‑class and best‑in‑class programs across multiple indications and modalities. The platform is designed to accelerate target‑to‑candidate timelines and has been used in rapid-response collaborations and clinical‑stage antibody programs.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for AbCellera.
We're Not Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn
Dec 25, 2025
Computational Biologics Design – Associate Principal Scientist
AstraZeneca
Protein Engineer
Xaira Therapeutics
Computational Protein Design Scientist
MSD
Scientist - AI & ML for Protein and Antibody Engineering
Roche
Computational Protein Design Scientist
MSD
Protein Bioinformatics - Postdoctoral Researcher
LLNL